Since many cancers overexpress the thioredoxin system, which confers drug resistance to cancer chemotherapy, there has been growing evidence in recent years that TrxR is a potential target for developing new anti-cancer drugs (Kim et al., 2005). This evidence concerns the gene TXN and cancer.